| [1] |
Sirachainan N, Pakakasama S, Anurathapan U, et al. Outcome of newly diagnosed high risk medulloblastoma treated with carboplatin, vincristine, cyclophosphamide and etoposide[J]. J Clin Neurosci, 2018, 56: 139-142.
|
| [2] |
Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables[J]. J Clin Oncol, 2011, 29(11): 1400-1407.
|
| [3] |
Kumar V, Kumar V, McGuire T, et al. Challenges and recent advances in medulloblastoma therapy[J]. Trends Pharmacol Sci, 2017, 38(12): 1061-1084.
|
| [4] |
Qin C, Pan Y, Li Y, et al. Novel molecular hallmarks of group 3 medulloblastoma by single-cell transcriptomics[J]. Front Oncol, 2021, 11: 622430.
|
| [5] |
Wen J, Hadden MK. Medulloblastoma drugs in development: current leads, trials and drawbacks[J]. Eur J Med Chem, 2021, 215: 113268.
|
| [6] |
Wang J, Garancher A, Ramaswamy V, et al. Medulloblastoma: from molecular subgroups to molecular targeted therapies[J]. Annu Rev Neurosci, 2018, 41: 207-232.
|
| [7] |
Ramaswamy V, Taylor MD. Medulloblastoma: from myth to molecular[J]. J Clin Oncol, 2017, 35(21): 2355-2363.
|
| [8] |
Kline CN, Packer RJ, Hwang EI, et al. Case-based review: pediatric medulloblastoma[J]. Neurooncol Pract, 2017, 4(3): 138-150.
|
| [9] |
Tomasello F, Conti A, Cardali S, et al. Telovelar approach to fourth ventricle tumors: highlights and limitations[J]. World Neurosurg, 2015, 83(6): 1141-1147.
|
| [10] |
陈立华，刘运生，袁贤瑞, 等. 儿童髓母细胞瘤显微手术治疗[J]. 中国当代儿科杂志, 2002, 4(6): 478-481.
|
| [11] |
Atallah A, Rady MR, Kamal HM, et al. Telovelar approach to pediatric fourth ventricle tumors: feasibility and outcome[J]. Turk Neurosurg, 2019, 29(4): 497-505.
|
| [12] |
Winkler EA, Birk H, Safaee M, et al. Surgical resection of fourth ventricular ependymomas: case series and technical nuances[J]. J Neurooncol, 2016, 130(2): 341-349.
|
| [13] |
Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495.
|
| [14] |
Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968.
|
| [15] |
Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial[J]. Lancet Oncol, 2006, 7(10): 813-820.
|
| [16] |
Thompson EM, Ashley D, Landi D. Current medulloblastoma subgroup specific clinical trials[J]. Transl Pediatr, 2020, 9(2): 157-162.
|
| [17] |
Ramaswamy V, Remke M, Shih D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent[J]. Pediatr Blood Cancer, 2014, 61(7): 1190-1194.
|
| [18] |
Massimino M, Biassoni V, Gandola L, et al. Childhood medulloblastoma[J]. Crit Rev Oncol Hematol, 2016, 105: 35-51.
|
| [19] |
Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (pog 9031)[J]. J Clin Oncol, 2013, 31(23): 2936-2941.
|
| [20] |
Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the milan strategy for metastatic medulloblastoma[J]. J Clin Oncol, 2009, 27(4): 566-571.
|